Table 1. Crude and adjusted maternal and infant outcomes amongst women who received and did not receive CBS in South Africa.
| Received CBS | Did not receive CBS | Crude effect measure (95% CI) (CBS vs. no CBS) | Crude P-value | Adjusted effect measure (95% CI) | Adjusted P-value | |
|---|---|---|---|---|---|---|
| Women eligible to initiate triple ART who failed to initiate triple ART antenatally, n/N (%) | 6/112 (5.4%) | 88/290 (30.3%) | 0.17 (0.07–0.39)a | <.0001 | 0.18 (0.08–0.44)a | <.0001 |
| Time till initiating triple ART from the first antenatal visit, median, days (IQR)c | 26 (13–49) | 39 (22–72) | 1.49 (1.12–1.97)b | .006 | 1.57 (1.15–2.14)b | .004 |
| Women eligible to initiate antenatal ZDV who failed to initiate ZDV, n/N (%) | 5/86 (5.8%) | 36/392 (9.2%) | 0.63 (0.26–1.57)a | .32 | 1.13 (0.33–3.92)a | .85 |
| Time till initiating antenatal ZDV since eligibility, median, days (IQR)d | 0 (0–0) | 1 (0–28) | 1.66 (1.30–2.11)b | <.0001 | 1.52 (1.18–2.01)b | .001 |
| Proportion of all women who received ART by delivery, n/N (%) | 171/264 (64.8%) | 324/841 (38.5%) | 1.68 (1.49–1.90)a | <.0001 | 1.30 (1.15–1.47)a | <.0001 |
| Stillbirths, n/N (%) | 4/264 (1.5%) | 45/841 (5.4%) | 0.27 (0.10–0.76)a | .0067 | 0.24 (0.07–1.00)a | .050 |
| Positive infant PCR tests around six weeks of age, n/N (%) | 3/76 (3.95%) | 13/392 (3.32%) | 1.19 (0.35–4.07)a | .782 | 1.15 (0.29–4.40)a | .84 |
Note: ART, antiretroviral treatment; ZDV, zidovudine; PCR, HIV deoxyribonucleic acid polymerase chain reaction; IQR, interquartile range.
aRR (95% confidence interval).
bHR (95% confidence interval).
cAmongst women who commenced triple ART antenatally.
dAmongst women who initiated ZDV antenatally. For women with zero survival time, 0.1 day was added to survival times in order to include subjects in the analysis.